Bausch Health vs Hyundai: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Bausch Health and Hyundai side by side

1. 1959Bausch Health

   Milan Panic founds ICN Pharmaceuticals

   Milan Panic, a Yugoslav immigrant to California, founded ICN Pharmaceuticals in 1959 and ran it for four decades. ICN is the predecessor of Valeant Pharmaceuticals and of today's Bausch Health.

2. 1967Hyundai

   Hyundai Motor Company Founded

   Chung Ju-yung established Hyundai Motor Company, creating the automotive arm that would become the flagship of South Korea's car industry.

3. 1975Hyundai

   Hyundai Pony

   The Hyundai Pony became Korea's first mass-produced passenger car and gave Hyundai a domestic platform for exports and engineering learning.

4. 1986Hyundai

   U.S. Market Entry

   Hyundai entered the U.S. market with the Excel, rapidly building awareness as a value-oriented global automaker.

5. 1994Bausch Health

   Biovail Corporation International formed in Canada

   On March 29, 1994 Eugene Melnyk consolidated his Canadian drug-delivery business by amalgamating Trimel Corporation with its subsidiary to create Biovail Corporation International, the legal entity that files today as Bausch Health Companies Inc.

6. 1998Hyundai

   Kia Stake Acquired

   Hyundai acquired a controlling stake in Kia during the Asian financial crisis, creating the basis for Hyundai Motor Group's modern platform scale.

7. 2003Bausch Health

   ICN renames itself Valeant Pharmaceuticals

   ICN Pharmaceuticals, then based in Costa Mesa, California, took the Valeant Pharmaceuticals name in November 2003 to distance itself from the governance fights of the Panic era.

8. 2008Bausch Health

   J. Michael Pearson becomes chief executive

   Valeant appointed former McKinsey director J. Michael Pearson as chief executive effective February 1, 2008, succeeding Timothy C. Tyson. Pearson replaced internal research spending with debt-funded acquisitions of marketed drugs.

9. 2010Bausch Health

   Biovail and Valeant complete their merger

   The merger of Biovail Corporation and Valeant Pharmaceuticals International closed on September 28, 2010. The combined company kept the Valeant name and Pearson as chief executive but was incorporated in Canada.

10. 2011Bausch Health

    Ortho Dermatologics bought from Johnson and Johnson

    Valeant agreed to acquire the U.S. Ortho Dermatologics assets from Janssen Pharmaceuticals, a Johnson and Johnson company, for about $345M in cash, building the dermatology franchise.

11. 2013Bausch Health

    Bausch + Lomb acquired for $8.7 billion

    Valeant agreed in May 2013 to buy eye-health company Bausch + Lomb from Warburg Pincus for $8.7B in cash, adding contact lenses, lens care, ophthalmic drugs and surgical devices.

12. 2015Bausch Health

    Salix acquisition closes at about $11.1 billion

    Valeant completed its tender offer for Salix Pharmaceuticals on April 1, 2015 at $173 per share, about $11.1B in equity value and roughly $15.8B including debt, gaining the Xifaxan franchise.

13. 2015Bausch Health

    Drug pricing and Philidor scandal breaks

    Congressional investigators pressed Valeant over 525% and 212% increases on the heart drugs Isuprel and Nitropress, bought in February 2015, and over its undisclosed ties to the Philidor mail-order pharmacy.

14. 2015Hyundai

    Genesis Luxury Brand

    Hyundai launched Genesis as a standalone luxury brand, supporting premiumization and higher-margin global growth.

15. 2016Bausch Health

    Joseph Papa replaces Pearson as chief executive

    Valeant named Perrigo chief executive Joseph C. Papa as chairman and CEO on April 25, 2016, and he took over in early May 2016 with about $30B of debt outstanding.

16. 2017Bausch Health

    Skincare brands and Dendreon sold to cut debt

    Valeant sold the CeraVe, AcneFree and AMBI skincare brands to L'Oreal for about $1.3B and the Dendreon cancer unit to China's Sanpower Group for about $820M, using the proceeds to repay debt.

17. 2018Bausch Health

    Company renamed Bausch Health Companies Inc.

    The name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. was completed on July 13, 2018, and the shares began trading as BHC on the NYSE and TSX on July 16, 2018.

18. 2020Bausch Health

    SEC settlement closes the Philidor accounting case

    On July 31, 2020 Bausch Health agreed to pay a $45M civil penalty to settle SEC charges of improper revenue recognition and misleading disclosures tied to Philidor. Former chief executive J. Michael Pearson and two other executives also settled.

19. 2020Hyundai

    E-GMP EV Platform

    Hyundai introduced its dedicated E-GMP electric-vehicle platform, giving models such as Ioniq 5 and Ioniq 6 fast-charging and packaging advantages.

20. 2021Hyundai

    Boston Dynamics Acquisition

    Hyundai Motor Group acquired a controlling stake in Boston Dynamics, adding robotics to its long-term mobility and automation strategy.

21. 2022Bausch Health

    Bausch + Lomb listed on the NYSE and TSX

    Bausch + Lomb common stock began trading under the ticker BLCO on May 6, 2022, and a Bausch Health subsidiary sold 35,000,000 Bausch + Lomb shares in the offering. Bausch Health retained about 88% of the eye-health company and still consolidates it. Thomas J.

22. 2025Bausch Health

    DURECT acquired and record annual revenue reported

    Bausch Health closed the DURECT acquisition on September 11, 2025 for about $63M upfront, completed Solta Medical's Chinese aesthetics distribution purchase on December 1, 2025, and reported FY2025 revenue of $10.266B, up 7%, with net income attributable to Ba…

23. 2025Hyundai

    Jose Munoz Becomes CEO

    Jose Munoz, previously Hyundai's global COO and head of its North American business, became President and CEO effective January 1, 2025, succeeding Jaehoon Chang. He is the first non-Korean to lead the company.

24. 2025Hyundai

    Record Revenue, Tariff-Hit Profit

    Hyundai reported FY2025 revenue of ~$132 billion (KRW 186.25 trillion), up 6.3%, while operating profit fell 19.5% to ~$8.14 billion (KRW 11.47 trillion) and net profit fell 21.7% to ~$7.36 billion (KRW 10.36 trillion), largely due to U.S. tariffs.

25. 2025Hyundai

    Georgia Battery Plant Raid

    In September 2025, U.S. immigration agents detained hundreds of workers, many of them Korean, at the Hyundai-LG Energy Solution battery plant under construction in Georgia, delaying its opening by months.

26. 2026Bausch Health

    RED-C trials miss endpoints and trigger a $1.4 billion charge

    In January 2026 the two Phase 3 RED-C trials of amorphous-rifaximin soluble solid dispersion for primary prevention of hepatic encephalopathy missed their primary endpoints.

27. 2026Bausch Health

    Second-quarter 2026 revenue of $2.85 billion and raised guidance

    Bausch Health reported second-quarter 2026 revenue of $2.85B, up 13%, net income attributable to Bausch Health of $258M and adjusted EBITDA of $1.075B, and raised its full-year 2026 revenue, adjusted EBITDA and cash flow guidance.

28. 2026Hyundai

    Full Ownership of Boston Dynamics

    In July 2026 Hyundai Motor Group moved to buy SoftBank's remaining stake in Boston Dynamics, a deal reported at about $325 million, making the robotics company wholly owned.

29. 2026Hyundai

    2026 CEO Investor Day

    At its August 2026 CEO Investor Day, Hyundai reaffirmed a 2030 target of 5.55 million global sales and detailed its $26 billion U.S. investment plan through 2028.

Acquisitions

Questions about Bausch Health vs Hyundai